Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia (2024)

First Author: Cogswell T
Attributed to:  The Epigenetic Control of Gene Expression in Leukaemia and Haematopoiesis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1039/d4md00275j

PubMed Identifier: 39220761

Publication URI: http://europepmc.org/abstract/MED/39220761

Type: Journal Article/Review

Parent Publication: RSC Medicinal Chemistry

Issue: 10

ISSN: 2632-8682